# A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

> **NCT06754930** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** SHR-1826
- **DRUG:** SHR-1316
- **DRUG:** SHR-9839
- **DRUG:** SHR-8068
- **DRUG:** Ametinib mesylate
- **DRUG:** BP-102
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06754930
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754930, "A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06754930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*